Bachem has announced that the company, on 16 June 2010, sold its complete stake in Polyphor to Ingro Finanz, which hereby increased its stake in Polyphor to 29%. The involved parties have agreed not to disclose the purchase price of the transaction.
For more than ten years Bachem and Polyphor have been working closely together. In the frame of this collaboration, Bachem in 1999 had taken a 31% stake in the 1996-founded Polyphor. Lately Bachem's share in Polyphor was at 16%.
Following the discontinuation of the financial involvement, a supply agreement governs the further collaboration between Bachem and Polyphor. Based on the 'right of last refusal', also granted for the future, Bachem will remain supplier for the delivery of active peptide ingredients.
